PMID- 36974793 OWN - NLM STAT- MEDLINE DCOM- 20230329 LR - 20230329 IS - 1791-7530 (Electronic) IS - 0250-7005 (Linking) VI - 43 IP - 4 DP - 2023 Apr TI - Significance of MYB and NTRK Expression in Head and Neck Adenoid Cystic Carcinoma. PG - 1709-1717 LID - 10.21873/anticanres.16323 [doi] AB - BACKGROUND/AIM: Adenoid cystic carcinoma (ACC) is an aggressive neoplasm even though it has low-grade histological appearance and slow growth. The aim of this study was to identify the immunohistochemical and molecular characteristics of ACC, as well as their correlation with the clinical course of patients. PATIENTS AND METHODS: This is a retrospective multicenter analysis. We included 50 patients diagnosed with ACC in the head and neck between 2000 and 2021. The expression of MYB proto-oncogene transcription factor (MYB), neurotrophic tyrosine kinase receptor (NTRK), human epidermal receptor-2 (HER-2), and Ki-67 was examined through immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). We also performed a clinical follow-up of the patients. RESULTS: The median age of the patients was 58.5 years; moreover, 54% of the patients were male. Compared with female patients, male patients were at a higher risk of both recurrence and death. No HER-2-positive cases were revealed. MYB expression was positive in 28 (56%) cases. However, MYB expression did not significantly affect survival. NTRK expression was positive in eight (16%) cases. NTRK-positive patients had worse overall survival (OS) than NTRK-negative patients (p=0.0246). Additionally, the percentage of NTRK-stained cells was negatively correlated with disease-free survival (p=0.0016) and OS (p=0.0027). CONCLUSION: There was no correlation between MYB positivity and survival. Contrarily, NTRK-positive patients had worse survival, indicating that NTRK is a negative prognostic factor. Tropomyosin receptor kinase inhibitors can be used to treat these patients. Furthermore, MYB-targeted inhibitors are promising therapeutic agents. CI - Copyright (c) 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. FAU - Pantazopoulos, Theodoros AU - Pantazopoulos T AD - 2 Department of Otolaryngology, "Attikon" University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; theopantazo@gmail.com. FAU - Leventakou, Danai AU - Leventakou D AD - 2 Department of Pathology, "Attikon" University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece. FAU - Koufopoulos, Nektarios AU - Koufopoulos N AD - 2 Department of Pathology, "Attikon" University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece. FAU - Pouliakis, Abraham AU - Pouliakis A AD - 2 Department of Pathology, "Attikon" University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece. FAU - Economopoulou, Panagiota AU - Economopoulou P AD - Department of Internal Medicine, Section of Medical Oncology, "Attikon" University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece. FAU - Glava, Chryssoula AU - Glava C AD - Department of Pathology, Korgialenio-Benakio Hellenic Red Cross General Hospital, Athens, Greece. FAU - Tzardi, Maria AU - Tzardi M AD - Department of Pathology, University General Hospital of Heraklion, Medical School, University of Crete, Heraklion, Greece. FAU - Kafiri, Georgia AU - Kafiri G AD - Department of Pathology, Hippokration General Hospital, Athens, Greece. FAU - Kittas, Christos AU - Kittas C AD - Department of Pathology, Bioiatriki Healthcare Group, Athens, Greece. FAU - Korkolopoulou, Penelope AU - Korkolopoulou P AD - 1 Department of Pathology, Laikon General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece. FAU - Arapantoni-Dadioti, Petroula AU - Arapantoni-Dadioti P AD - Department of Pathology, Henry Dunant Hospital Center, Athens, Greece. FAU - Sotiriou, Helen AU - Sotiriou H AD - Department of Pathology, Saint Panteleimon General State Hospital, Nikea, Greece. FAU - Filippidis, Theodoros AU - Filippidis T AD - Department of Pathology, Micromedica Labs, Athens, Greece. FAU - Maragoudakis, Pavlos AU - Maragoudakis P AD - 2 Department of Otolaryngology, "Attikon" University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece. FAU - Giotakis, Ioannis AU - Giotakis I AD - 2 Department of Otolaryngology, "Attikon" University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece. FAU - Panayiotides, Ioannis G AU - Panayiotides IG AD - 2 Department of Pathology, "Attikon" University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece. FAU - Psyrri, Amanda AU - Psyrri A AD - Department of Internal Medicine, Section of Medical Oncology, "Attikon" University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece. FAU - Delides, Alexandros AU - Delides A AD - 2 Department of Otolaryngology, "Attikon" University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece. LA - eng PT - Journal Article PT - Multicenter Study PL - Greece TA - Anticancer Res JT - Anticancer research JID - 8102988 RN - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - Male MH - Female MH - Middle Aged MH - *Carcinoma, Adenoid Cystic/pathology MH - Receptor Protein-Tyrosine Kinases MH - In Situ Hybridization, Fluorescence MH - *Head and Neck Neoplasms/genetics MH - Immunohistochemistry MH - Biomarkers, Tumor/metabolism OTO - NOTNLM OT - Adenoid cystic carcinoma OT - HER-2 OT - Ki-67 OT - MYB OT - NTRK EDAT- 2023/03/29 06:00 MHDA- 2023/03/29 06:05 CRDT- 2023/03/28 05:33 PHST- 2023/01/30 00:00 [received] PHST- 2023/02/13 00:00 [revised] PHST- 2023/02/14 00:00 [accepted] PHST- 2023/03/29 06:05 [medline] PHST- 2023/03/28 05:33 [entrez] PHST- 2023/03/29 06:00 [pubmed] AID - 43/4/1709 [pii] AID - 10.21873/anticanres.16323 [doi] PST - ppublish SO - Anticancer Res. 2023 Apr;43(4):1709-1717. doi: 10.21873/anticanres.16323.